Recombinant Human Anti-CD3 x Human Anti-CD248 Bispecific Antibody (Fv-IgG) (BSDG-H254)

Recombinant Anti-CD3 x Anti-CD248 Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD3 IgG with similar domains from an anti-CD248 antibody via short peptide linkers, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & CD248

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Solid tumors

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

CD248

Gene ID

57124

UniProt ID

Q9HCU0

Alternative Names

CD248; CD248 molecule, endosialin; TEM1; CD164L1; endosialin; 2610111G01Rik; CD164 sialomucin-like 1; CD248 antigen, endosialin; tumor endothelial marker 1

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD3 x Human Anti-CD248 Bispecific Antibody (Fv-IgG) (BSDG-H254). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD3 x Human Anti-CD248 Bispecific Antibody (Fv-IgG) (CAT#: BSDG-H254)

Specifications

Targets

Customer Reviews and Q&As